regardless of encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from pharmacy benefit managers. The companies are frequently building obstacles to reimbursement, such as steep cost requirements and approval processes that restrict user avai… Read More